Global mRNA Vaccine and Therapeutics Market – Analysis By Product, End User, By Region, By Country (2021 Edition): Market Insights and Forecast with Impact of Covid-19 (2021-2030)

Global mRNA Vaccine and Therapeutics Market – Analysis By Product, End User, By Region, By Country (2021 Edition): Market Insights and Forecast with Impact of Covid-19 (2021-2030)

Executive Summary

The mRNA technology finds its applications in many diseases including the Covid-19 vaccine. The market for mRNA is mostly driven by the Covid-19 vaccine besides its major usage in cancer therapies. With the mutation of the coronavirus and possible spread of variants of the virus, the mRNA companies are actively engaged in developing next generation vaccines for Covid-19.

The Global mRNA Vaccine and Therapeutic Market is estimated at USD 29672.31 Million in the year 2025. The growing occurrences of chronic and infectious diseases, such as diabetes, HIV, cancer and CVDs, is one of the major key factors driving the growth of the market. The growing demand for therapeutic medicines and vaccines for Ebola, influenza, Human Immunodeficiency Virus (HIV) and other viral infections as well as inability of traditional vaccine approach to find vaccines at the critical time are also providing a boost to the market growth. Compared to conventional medicines, mRNA vaccines and Therapeutics are developed with the help of advanced technologies which are more effective against pathogens, have higher effectiveness, improved immunogenicity and require less cost to produce. Moreover, developments in the lipid nanoparticle formulations for in-vivo systemic delivery of mRNA are also creating a positive outlook for the market growth.

Covid-19 vaccines are expected to hold largest share of mRNA Vaccine and Therapeutics market. The standardisation of cancer treatment segment, during the forecast period 2026-2030 is expected to be the largest contributor to the market growth. The major reason is the increase in the number of cancer patient around the world and it becomes imperative to have a set of standards for its treatment.

North America holds the largest share of the mRNA vaccines and therapeutics market for non-Covid-19 vaccines due to the growing need to develop transformative therapeutics, increasing fund infusions, a favorable regulatory environment, and massively growing attention to establish precision medicine, among others. Rising prevalence of cancer and other diseases among the developing economies of Asia region is augmenting the demand of mRNA Vaccine and Therapeutics in APAC region.

Scope of the Report

  • The report analyses the mRNA Vaccine and Therapeutic Market by value (USD Million).
  • The report analyses the mRNA Vaccine and Therapeutic Market by Product (COVID Vaccines, Infectious Disease Vaccines, Cancer Vaccines, Autoimmune Diseases and Others).
  • The report analyses the mRNA Vaccine and Therapeutic Market by End User (Hospitals & Clinics, Research Organization and Others).
  • The Global mRNA Vaccine and Therapeutic Market has been analysed By Region (North America Europe, Asia Pacific, LAMEA) By Country (United States, Canada, Germany, U.K, France, Switzerland, Russia, China, Japan, and India).
  • The key insights of the report have been presented through the frameworks of the attractiveness of the market has been presented by region, by product, By End User.
  • Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include AstraZeneca Plc, Bayer Group, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Moderna, BioNtech, Sangamo Therapeutics, Crispr Therapeutics, Intellia Therapeutics.
  • The report presents the analysis of mRNA Vaccine and Therapeutic market for the forecast period of 2021-2030.
Key Target Audience
  • Biotechnology Companies
  • Pharmaceutical and Healthcare Companies
  • Consulting and Advisory Firms
  • Government and Policy Makers
  • Regulatory Authorities


1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2.Strategic Recommendations
3. mRNA Vaccine and Therapeutics Market: Product Outlook
4. Global mRNA Vaccine and Therapeutics Market: Sizing and Forecast
4.1 Global mRNA Vaccine and Therapeutics Market Size, By Value, Year 2021-2030
Table 1: Global mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Table 2: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 3: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 4: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 5: Global Expenses (% GDP), 2015-2019
Table 6: GDP per Capita Growth (annual %), 2015-2019
Table 7: World Population 65 Years & Above (% of Total), 2015-2019
Table 8: Daily Covid-19 vaccine doses administered per 100 people , Feb 3, 2021 (In Millions)
Table 9: Total no. of Covid-19 vaccination administered, Feb 3, 2021 (In Millions)
Table 10: Share of people who received at least one dose of covid-19 vaccine, Feb 3, 2021 (In %)
Table 11: Share of the population fully vaccinated against covid-19, Feb 3, 2021 (In %)
Table 12: Global Number of deaths in 2020, all cancers, males and females, all ages, (In Numbers)
Table 13: Global Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
5.Global mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User
5.1 Competitive Scenario of Global mRNA Vaccine and Therapeutics Market: By Product
Table 14: Global mRNA Vaccine and Therapeutics Market- By Product Market Share, 2025 & 2030
5.1.1 COVID Vaccines - Market Size and Forecast (2021-2030)
Table 15: Global mRNA Vaccine and Therapeutics Market- By COVID vaccines, By Value (USD Million), 2021-2030
5.1.2 Infectious Disease Vaccines - Market Size and Forecast (2021-2030)
Table 16: Global mRNA Vaccine and Therapeutics Market- By Infectious Disease vaccines, By Value (USD Million), 2021-2030
5.1.3 Cancer Vaccines - Market Size and Forecast (2021-2030)
Table 17: Global mRNA Vaccine and Therapeutics Market- By Cancers vaccines, By Value (USD Million), 2021-2030
5.1.4 Autoimmune Diseases - Market Size and Forecast (2021-2030)
Table 18: Global mRNA Vaccine and Therapeutics Market- By Autoimmune Diseases, By Value (USD Million), 2021-2030
5.1.5 Others - Market Size and Forecast (2021-2030)
Table 19: Global mRNA Vaccine and Therapeutics Market- By Others, By Value (USD Million), 2021-2030
5.2 Competitive Scenario of Global mRNA Vaccine and Therapeutics Market: By End User
Table 20: Global mRNA Vaccine and Therapeutics Market- By End User Market Share, 2025 & 2030
5.2.1 Hospitals & Clinics - Market Size and Forecast (2021-2030)
Table 21: Global mRNA Vaccine and Therapeutics Market- By Hospitals & Clinics, By Value (USD Million), 2021-2030
5.2.2 Research & Organizations - Market Size and Forecast (2021-2030)
Table 22: Global mRNA Vaccine and Therapeutics Market- By Research Organizations, By Value (USD Million), 2021-2030
5.2.3 Others ñ-Market Size and Forecast (2021-2030)
Table 23: Global mRNA Vaccine and Therapeutics Market- By Others, By Value (USD Million), 2021-2030
6. Global mRNA Vaccine and Therapeutics Market: Regional Analysis
6.1 Competitive Scenario of Global mRNA Vaccine and Therapeutics Market: By Region
Table 24: Global mRNA Vaccine and Therapeutics Market- By Region Market Share, 2025 & 2030
7.North America mRNA Vaccine and Therapeutics Market : An Analysis
7.1 North America mRNA Vaccine and Therapeutics Market : Size and Forecast (2021-2030), By Value
Table 25: North America mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Table 26: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 27: North America Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 28: North America Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 29: North America Urban population, 2015-2018 (In %)
Table 30: North America Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
7.2 North America mRNA Vaccine and Therapeutics Market - Prominent Companies
7.3 Market Segmentation By Product (COVID Vaccines, Infectious Disease Vaccines, Cancer Vaccines, Autoimmune Diseases, Others)
Table 31: North America mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
7.4 Market Segmentation End User (Hospitals & Clinics, Research & Organizations, and Others )
Table 32: North America mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
7.5 North America mRNA Vaccine and Therapeutics Market: Country Analysis
7.6 Market Opportunity Chart of North America mRNA Vaccine and Therapeutics Market - By Country, By Value, 2030
Table 33: Market Opportunity Chart of North America mRNA Vaccine and Therapeutics Market- By Country, By Value (Year-2030
7.7 Competitive Scenario of North America mRNA Vaccine and Therapeutics Market: By Country
Table 34: North America mRNA Vaccine and Therapeutics Market- By Country Market Share, 2025 & 2030
7.8 United States mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
Table 35: United States mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Table 36: United State Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 37: United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 38: United State Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 39: United States Urban population, 2016-2019 (In %)
7.9 United States mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
Table 40: United State mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Table 41: United State mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
7.10 Canada mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
Table 42: Canada mRNA Vaccine and Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Table 43: Canada Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 44: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 45: Canada Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 46: Canada Urban population, 2015-2019 (In %)
7.11 Canada mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
Table 47: Canada mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Table 48: Canada mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
8.Europe mRNA Vaccine and Therapeutics Market : An Analysis
8.1 Europe mRNA Vaccine and Therapeutics Market : Size and Forecast (2021-2030), By Value
Table 49: Europe mRNA Vaccine and Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Table 50: Europe Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 51: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 52: Europe Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 53: Europe Urban population, 2015-2019 (In %)
Table 54: Europe Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
8.2 Europe mRNA Vaccine and Therapeutics Market - Prominent Companies
8.3 Market Segmentation By Product (COVID Vaccines, Infectious Disease Vaccines, Cancer Vaccines, Autoimmune Diseases, Others)
Table 55: Europe mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
8.4 Market Segmentation End User (Hospitals & Clinics, Research & Organizations, and Others )
Table 56: Europe mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
8.5 Europe mRNA Vaccine and Therapeutics Market: Country Analysis
8.6 Market Opportunity Chart of Europe mRNA Vaccine and Therapeutics Market - By Country, By Value, 2030
Table 57: Market Opportunity Chart of Europe mRNA Vaccine and Therapeutics Market- By Country, By Value (Year-2030)
8.7 Competitive Scenario of North America mRNA Vaccine and Therapeutics Market: By Country
Table 58: Europe mRNA Vaccine and Therapeutics Market- By Country Market Share, 2025 & 2030
8.8 Germany mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
Table 59: Germany mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Table 60: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 61: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 62: Germany Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 63: Germany Urban population, 2015-2019 (In %)
8.9 Germany mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
Table 64: Germany mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Table 65: Germany mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
8.10 United Kingdom mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
Table 66: United Kingdom mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Table 67: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 68: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 69: United Kingdom Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 70: United Kingdom Urban population, 2015-2019 (In %)
8.11 United Kingdom mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
Table 71: United Kingdom mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Table 72: United Kingdom mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
8.12 France mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
Table 73: France mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Table 74: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 75: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 76: France Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 77: France Urban population, 2015-2019 (In %)
8.13 France mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
Table 78: France mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Table 79: France mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
8.14 Switzerland mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
Table 80: Switzerland mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Table 81: Switzerland Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 82: Switzerland Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 83: Switzerland Domestic Private Health Expenditure as % of Current Health
Table 84: Switzerland Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
8.15 Switzerland mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
Figure 85: Switzerland mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Table 86: Switzerland mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
8.16 Russia mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
Table 87: Russia mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Table 88: Russia Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 89: Russia Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 90: Russia Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 91: Russia Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
8.17 Russia mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
Table 92: Russia mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Table 93: Russia mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
9.Asia Pacific mRNA Vaccine and Therapeutics Market : An Analysis
9.1 Asia Pacific mRNA Vaccine and Therapeutics Market : Size and Forecast (2021-2030), By Value
Table 94: Asia Pacific mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Table 95: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 96: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 97: Asia Pacific Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 98: Asia Pacific Urban population, 2015-2019 (In %)
Table 99: Asia pacific Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
9.2 Asia Pacific mRNA Vaccine and Therapeutics Market - Prominent Companies
9.3 Market Segmentation By Product (COVID Vaccines, Infectious Disease Vaccines, Cancer Vaccines, Autoimmune Diseases, Others)
Table 100: Asia Pacific mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
9.4 Market Segmentation End User (Hospitals & Clinics, Research & Organizations, and Others )
Table 101: Asia Pacific mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
9.5 Asia Pacific mRNA Vaccine and Therapeutics Market: Country Analysis
9.6 Market Opportunity Chart of Asia Pacific mRNA Vaccine and Therapeutics Market - By Country, By Value, 2030
Table 102: Market Opportunity Chart of APAC mRNA Vaccine and Therapeutics Market- By Country, By Value (Year-2030)
9.7 Competitive Scenario of Asia Pacific mRNA Vaccine and Therapeutics Market: By Country
Table 103: APAC mRNA Vaccine and Therapeutics Market- By Country Market Share, 2025 & 2030
9.8 China mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
Table 104: China mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Table 105: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 106: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 107: China Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 108: China Urban Population (%) of total population, 2016-2020
9.9 China mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
Table 109: China mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Table 110: China mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
9.10 Japan mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
Table 111: Japan mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Table 112: Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 113: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Table 114: Japan Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 115: Japan Urban Population (%) of total population, 2016-2020
9.11 Japan mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
Table 116: Japan mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Table 117: Japan mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
9.12 India mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
Table 118: India mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Table 119: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 120: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 121: India Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 122: India Urban Population (%) of total population, 2016-2020
9.13 India mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
Table 123: India mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Table 124: India mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
10.Global mRNA Vaccine and Therapeutics Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11.Market Attractiveness
11.1 Market Attractiveness Chart of Global mRNA Vaccine and Therapeutics Market - By Product, 2030
Table 125: Market Attractiveness Chart of Global mRNA Vaccine and Therapeutics Market- By Product (Year-2030)
11.2 Market Attractiveness Chart of Global mRNA Vaccine and Therapeutics Market - By End User,
Table 126: Market Attractiveness Chart of Global mRNA Vaccine and Therapeutics Market- By End User (Year-2030)
11.3 Market Attractiveness Chart of Global mRNA Vaccine and Therapeutics Market - By Region, 2030
Table 127: Market Attractiveness Chart of Global mRNA Vaccine and Therapeutics Market- By Region (Year-2030)
12. Competitive Landscape
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
13.mRNA Vaccine and Therapeutics Pipeline Development
13.1 mRNA vaccine development pipeline for infectious diseases
Table A: mRNA vaccine development pipeline for infectious diseases
13.2 mRNA cancer therapies in development
Table B: mRNA cancer therapies in development
13.3 mRNA-based protein therapeutics in development
Table C: mRNA-based protein therapeutics in development
14. Regulatory Compliance
15.Company Analysis
15.1 AstraZeneca Plc
Table 128: AstraZeneca Sales Revenues, 2016-2020 (USD Million)
Table 129: AstraZeneca Gross Profit, 2016-2020 (USD Million)
Table 130: AstraZeneca Plc Sales Revenue Split, By Business Segment (%), FY2020
Table 131: AstraZeneca Plc Sales Revenue Split, By Geography Segment (%), FY2020
15.2 Bayer Group
Table 132: Bayer Group Revenues, 2016-2020 (USD Million)
Table 133: Bayer Group Net Income, 2016-2020 (USD Million)
Table 134: Bayer Group Sales Revenue Split, By Business Segment (%), FY2020
Table 135: Bayer Group Sales Revenue Split, By Geography Segment (%), FY2020
15.3 Boehringer Ingelheim
Table 136: Boehringer Ingelheim Revenues, 2016-2020 (USD Million)
Table 137: Boehringer Ingelheim Net Income/Loss, 2016-2020 (USD Million)
Table 138: Boehringer Ingelheim Sales Revenue Split, By Business Segment (%), FY2020
Table 139: Boehringer Ingelheim Sales Revenue Split, By Geography Segment (%), FY2020
15.4 GlaxoSmithKline
Table 140: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Table 141: GlaxoSmithKline Net Profit (USD Million), 2016-2020
Table 142: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Table 143: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
15.5 Pfizer
Table 144: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Table 145: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Table 146: Pfizer Sales Revenue Split, By Geography Segment (USD Million), FY2020
Table 147: Pfizer Sales Revenue Split, By Geography Segment (USD Million), FY2019
15.6 Moderna
Table 148: Moderna Annual Sales Revenue (USD Million), 2016-2020
Table 149: Moderna collaboration Revenue (USD Million), 2016-2020
Table 150: Moderna Sales Revenue Split, By Geography Segment (USD Million), FY2020
Table 151: Moderna Sales Revenue Split, By Geography Segment (USD Million), FY2019
15.7 BioNtech
Table 152: BioNTECH Annual Sales Revenue (USD Million), 2017-2020
Table 153: BioNTECH Profit/Loss (USD Million), 2017-2020
Table 154: BioNTech Sales Revenue Split, By Operating Segment (USD Million), FY2020
Table 155: BioNtech Sales Revenue Split, By Operating Segment (USD Million), FY2019
15.8 Sangamo Therapeutics
Table 156: Sangamo Therapeutics Annual Sales Revenue (USD Million), 2016-2020
Table 157: Sangamo Therapeutics Net Loss (USD Million), 2016-2020
15.9 Crispr Therapeutics
Table 158: Crispr Therapeutics Collaboration Revenue (USD Million), 2015-2019
Table 159: Crispr Therapeutics Net Income (USD Million), 2015-2019
15.10 Intellia Therapeutics

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook